Jefferies Maintains Bullish Stance on Acadia Pharmaceuticals (ACAD) after AAN Meeting
Tweet Send to a Friend
Jefferies reiterated its Buy rating and $13 price target Acadia Pharmaceuticals (NASDAQ: ACAD) following feedback at the American Academy of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE